A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS)

<div>Proportion of participants achieving ppPASI75 response by visit through week 48 (full analysis set). Data missing due to discontinuation of treatment are imputed with nonresponse (0). Data missing due to reasons other than discontinuation of treatment are imputed using multiple imputation. The ppPASI evaluates erythema, pustules, and desquamation on a 5-point scale (where 0 = absent and 4 = very severe) along with the extent to which the palms and/or soles are affected on a 6-point scale (where 0 = absent and 6 = 90–100%). In line with the inclusion criteria, the score for pustules was set at 0; thus, the index had a maximum score of 48. ppPASI75 response is defined as ≥75% improvement in the ppPASI score from the baseline. ppPASI, palmoplantar Psoriasis Area and Severity Index.</div>

Dermatologic Therapy

fig3

Figure 3

Figure 3: A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS) 

Figure 3 | A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS) 